On Tuesday, Oculus Innovative Sciences, Inc. (NASDAQ:OCLS)’s shares declined -8.51% to $1.29.
Oculus Innovative Sciences, Inc. (OCLS) (tradable warrants OCLSW) declared financial results for the first quarter of fiscal year 2016, which ended on June 30, 2015. Total revenue was $3.7 million for the first quarter, up 8%, when contrast to $3.4 million for the same period in fiscal year 2015. Product revenues were up 37% from the same period last year, led by enhances in the United States and Mexico.
Results for the Three Months Ended June 30, 2015
Product revenues in the United States were $787,000 for the three months ended June 30, 2015, as contrast to $355,000 in the quarter ended June 30, 2014. Product revenues were up $432,000, or 122%, from the same period last year due to higher sales in dermatology and acute care products. In the quarter ending December 2014, Oculus deployed a direct sales force focused on dermatology, which has launched four new dermatology products for the treatment of atopic dermatitis, scars and surgical procedures.
Product revenue in Mexico of $1.6 million for the three months ended June 30, 2015, raised by $465,000, or 43%, when contrast to the same period in the preceding year. On a local currency basis, product revenue growth was 68% contrast to the same period last year. This growth in sales is primarily due to the much larger sales force and distribution network of our new partner, Laboratorios Sanfer, which attained our former Latin American partner, More Pharma, in January 2015.
Oculus Innovative Sciences, Inc. designs, produces, and markets prescription and over-the-counter products based on its Microcyn platform technology for the dermatology, surgical, advanced tissue and skin care, and animal healthcare markets in the United States, Mexico, Europe, and internationally.
Plains GP Holdings LP (NYSE:PAGP)’s shares dropped -1.18% to $24.38.
Plains All American Pipeline, L.P. ( PAA ) and Plains GP Holdings ( PAGP ) stated second-quarter 2015 results.
PAA stated solid second quarter results, with adjusted EBITDA of $486 million, which was about $26 million above the mid-point of our quarterly guidance range, said Greg L. Armstrong, Chairman and CEO of Plains All American. PAA will pay a quarterly distribution of $0.695 per limited partner unit next week, which is the equivalent of $2.78 per unit on an annualized basis, while PAGP will pay a quarterly distribution of $0.227 per Class A share, or $0.908 per share on an annualized basis. These distributions represent a 7.8% and 23.8% enhance over comparative distributions paid in the same quarter of 2014, respectively.
Over the intermediate to long-term, we remain very constructive on the outlook for the North American crude oil industry. Near term, we are cautious as high crude oil and refined product inventory levels will influence oilfield activity and crude oil production levels over the next six to twelve months and competition for the marginal barrel will intensify. Additionally, our current forecast assumes that our All American pipeline in California will not be returned to service during the balance of 2015.
Second-quarter 2015 Transportation adjusted segment profit raised 12% as compared to comparable 2014 results. This enhance was driven by earnings from our 50% interest in the BridgeTex pipeline attained in November 2014 and higher crude oil pipeline volumes associated with recently accomplished organic growth projects primarily within the Permian Basin and Eagle Ford producing regions.
Second-quarter 2015 Facilities adjusted segment profit raised by 6% over comparable 2014 results. This enhance was primarily due to lower field operating costs associated with our NGL fractionation and Canadian natural gas processing activities.
Plains GP Holdings, L.P., through its interest in Plains AAP, L.P., owns and operates midstream energy infrastructure and provides logistics services for crude oil, natural gas liquids, natural gas, and refined products in the United States and Canada. The company operates through three segments: Transportation, Facilities, and Supply and Logistics. The Transportation segment is involved in transporting crude oil and NGL on pipelines, gathering systems, trucks, and barges. As of December 31, 2014, this segment had owned and leased assets comprising 17,800 miles of active crude oil and NGL pipelines and gathering systems; 29 million barrels of active, above-ground tank capacity; 800 trailers; and 149 transport and storage barges, in addition to 72 transport tugs.
At the end of Tuesday’s trade, Celldex Therapeutics, Inc. (NASDAQ:CLDX)‘s shares showed no change to $23.30.
Celldex Therapeutics, Inc. (CLDX) will release second quarter 2015 financial results on Monday, August 10, 2015 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m. EDT on the same day to review the second quarter 2015 financial results and to provide an update on key research and development and business objectives for the remainder of 2015.
Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The company’s lead drug candidates comprise rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma, in addition to in Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate in a randomized Phase IIb study for the treatment of triple negative breast cancer, in addition to in Phase II study for the treatment of metastatic melanoma.
C R Bard Inc (NYSE:BCR), ended its Tuesday’s trading session with 0.05% gain, and closed at $196.29.
- R. Bard, Inc. (BCR) declared that the U.S. Centers for Medicare and Medicaid Services (CMS) has approved a new technology add-on payment for the Lutonix® Drug-Coated Balloon (DCB) under the Medicare hospital inpatient prospective payment system. The purpose of the reimbursement is to assist cover additional cost to U.S. hospitals for treating Medicare beneficiaries with the Lutonix® DCB in the inpatient setting. CMS determined the amount of the add-on payment to be a maximum of $1,036 when DCBs are used for inpatient peripheral procedures and the total device costs exceed the allowance for existing DRG reimbursement. The add-on payment is effective October 1, 2015.
- R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The company offers vascular products, such as percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters; biopsy devices; and temporary pacing electrode catheters for the treatment of peripheral vascular disease and heart arrhythmias.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
